Is TB-500 Legal in Pennsylvania? How to Access It Legally

HealthRX.com

No listed legal route to compound TB-500 in Pennsylvania

Print or save as PDF

See the public record for TB-500

  • What it is / Synthetic 7-amino-acid fragment (residues 17 to 23) of thymosin beta-4 [1]
  • FDA approval / None; FDA found no approved TB-500 drug in the United States, UK, Canada or Australia and no European Medicines Agency authorization [1]
  • FDA compounding lists / On neither the pharmacy list nor the outsourcing-facility list [2][3][4]
  • Pennsylvania / Board pages cover licensing of pharmacies and physicians and do not name TB-500 [5][6]
  • HHS draft policy, filed Oct 28, 2026 / No enforcement action intended against qualifying compounders of TB-500 acetate; draft and non-binding [7][8]
  • Sport / Prohibited at all times by WADA [9][10]

What TB-500 is

A synthetic, N-acetylated 7-amino-acid fragment (residues 17 to 23, LKKTETQ) of the 43-amino-acid protein thymosin beta-4, not the full-length protein. 'TB-500' is a common name, and FDA found several salts and derivatives, including different active moieties, sold under it [1].

Why a Pennsylvania pharmacy has no listed basis to compound it

Federal law generally permits a state-licensed pharmacy to compound from a bulk substance only if it has an applicable USP or National Formulary monograph, is a component of an FDA-approved drug, or appears on FDA's list of permitted bulk substances [4]. FDA found no monograph and no approved drug containing TB-500 [1]. TB-500 appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) and is absent from the outsourcing-facility list (updated March 21, 2025) [2][3][4].

FDA's safety-risk page (content dated 04/22/2026) carries 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500' in the nominated-but-withdrawn table. FDA said it 'has not identified any human exposure data' on such products and that injectable peptides may pose immunogenicity risk from aggregation and impurities; removal from category 2 was not a finding of safety [11]. FDA staff proposed in July 2026 that neither the free base nor the acetate be listed, and the Pharmacy Compounding Advisory Committee voted the other way on July 23, 2026. That vote is advice only, and listing requires formal rulemaking [1][12][7].

Pennsylvania's pages and the draft HHS policy

The State Board of Pharmacy regulates pharmacy practice through licensure and discipline, and the State Board of Medicine licenses physicians and surgeons. Both pages describe case-by-case professional conduct rather than named drugs, and neither names TB-500 [5][6]. The limits described on this page come from federal sources [1][4].

HHS filed a draft enforcement-discretion policy on October 28, 2026 (Federal Register document 2026-22192, publication scheduled October 30, 2026) naming TB-500 among six peptides and covering TB-500 acetate by subcutaneous or intramuscular injection [7][8]. HHS 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician meeting conditions such as a single active ingredient and a patient-specific prescription. The notice says it 'does not establish any rights for any person and is not binding on HHS or the public' [7].

Questions worth asking

Choose the questions you want to keep

Human evidence and sport

FDA found no article in which TB-500 was given to a human, and there is no approved dose [1]. Its adverse-event database search through March 26, 2025 retrieved no TB-500 reports; its complaint system returned two cases about a blended TB-500 and BPC-157 product with no safety assessment [1]. WADA names 'Thymosin-beta4 and its derivatives e.g. TB-500' in S2.3 and prohibits it at all times, in and out of competition [9][10].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. According to the article, why can a Pennsylvania pharmacy not rely on a listed basis to prepare TB-500 from bulk powder?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Is TB-500 legal in Pennsylvania?
TB-500 is not FDA-approved and is on neither FDA bulk-substance list, so a Pennsylvania pharmacy has no listed basis to compound it from bulk powder [1][2][3][4]. The state board pages do not name the peptide, and they do not say whether possessing it is an offense [5][6].
Can a Pennsylvania doctor prescribe TB-500?
The draft HHS policy lists a patient-specific prescription as one condition of its proposed enforcement discretion, which covers TB-500 acetate by subcutaneous or intramuscular injection [7][8]. The draft does not approve TB-500 and does not place it on FDA's list of permitted bulk substances, and TB-500 is not on that list [4][7].
Is TB-500 the same as thymosin beta-4?
No. TB-500 is a synthetic 7-amino-acid, N-acetylated fragment (residues 17 to 23) of the 43-amino-acid protein thymosin beta-4 [1]. Human studies of full-length thymosin beta-4, including eye drops and an intravenous recombinant protein, do not show that TB-500 works or is safe [1][13][14].
Show all 14 referencesHide references
  1. U.S. Food and Drug Administration.
  2. U.S. Food and Drug Administration.
  3. U.S. Food and Drug Administration.
  4. Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
  5. Pharmacy | Department of State | Commonwealth of Pennsylvania.
  6. Medicine | Department of State | Commonwealth of Pennsylvania.
  7. Official web page.
  8. Official web page.
  9. World Anti-Doping Agency.
  10. World Anti-Doping Agency.
  11. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  12. U.S. Food and Drug Administration.
  13. Wang X, Liu L, Qi L, Lei C, Li P, Wang Y, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021.
  14. Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Clin Ophthalmol. 2015.
Evidence overview for Is TB-500 Legal in Pennsylvania? How to Access It Legally